2,6-Diamino-8-methyl-purin | 26216-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2,6-Diamino-8-methyl-purin
• 英文别名: 8-methyl-7(9)H-purine-2,6-diamine；8-methyl-7H-purine-2,6-diamine
• CAS: 26216-56-8
• 化学式: C₆H₈N₆
• 分子量: 164.17
• InChiKey: OFIKBTBTNDDTJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US20160257706A1

  公开（公告）日：2016-09-08

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  一种结构的化合物： 或其药用可接受的盐或组合物，用于治疗感染或暴露于HCV病毒或其他在本文中更详细描述的疾病的宿主。
• DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION
  申请人：IDENIX PHARMACEUTICALS, INC.

  公开号：US20140112886A1

  公开（公告）日：2014-04-24

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds comprise two 2′-methyl nucleotides linked according to Formula I: N 1 -L-N 2 (I) or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, isomeric form, tautomeric form or polymorphic form thereof; wherein N 1 , L and N 2 are as described herein.

  本文提供了用于治疗黄病毒科感染，包括HCV感染的化合物、组合物和方法。在某些实施方式中，披露了核苷类衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合给药。在某些实施方式中，所述化合物包括根据以下式I连接的两个2'-甲基核苷酸：N1-L-N2(I)或其药学上可接受的盐、酯、溶剂合物、立体异构体、同分异构体、互变异构体或其多形形式；其中N1、L和N2如本文所述。
• [EN] BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION<br/>[FR] NUCLÉOTIDES DE PURINE BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUÉ-4'-FLUORO-N6-SUBSTITUÉ-6-AMINO-2-SUBSTITUÉ POUR LE TRAITEMENT DE L'INFECTION PAR LE VIRUS DE L'HÉPATITE C
  申请人：ATEA PHARMACEUTICALS INC

  公开号：WO2018013937A1

  公开（公告）日：2018-01-18

  Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in need thereof. The host can be a human or any animal that carries the viral infection. Methods of treating a subject suffering from a condition related to viral infections are also provided.

  当以有效剂量给予宿主时，化合物I、化合物II、化合物III、化合物IV、化合物V、化合物VI、化合物VII、化合物VIII、化合物IX和化合物X对HCV病毒具有高活性。宿主可以是患有病毒感染的人类或任何动物。还提供了治疗与病毒感染相关疾病的方法。
• β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US10000523B2

  公开（公告）日：2018-06-19

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  结构的化合物： 或其药学上可接受的盐或组合物，用于治疗感染或暴露于 HCV 病毒的宿主或本文更全面描述的其他疾病。
• β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US10005811B2

  公开（公告）日：2018-06-26

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  结构的化合物： 或其药学上可接受的盐或组合物，用于治疗感染或暴露于 HCV 病毒的宿主或本文更全面描述的其他疾病。